Home / Events / Company News / A Potential CDx Biomarker For Targeted Therapy In Non-Small Cell lung Cancer——MET
A Potential CDx Biomarker For Targeted Therapy In Non-Small Cell lung Cancer——MET
Dec. 23 2022

The morbidity and mortality of lung cancer rank first among malignant tumors, and the disease burden is heavy. In recent years, targeted therapy for lung cancer has achieved rapid development, rare targets such as MET have received more and more attention, and various new drugs have been continuously developed.

There are various types of MET gene mutations. Abnormal expression levels of c-MET protein, gene amplification and gene mutation are closely related to the occurrence and development of cancer. The use of c-MET biomarkers for patient screening and stratification greatly improves the clinical research of MET-targeted drugs success rate.

For MET gene mutations, high protein expression and gene amplification, qRT-PCR (MET exon14 skipping detection), IHC (c-MET protein overexpression detection) and FISH (MET amplification detection) are commonly used method in clinical research. In addition, NGS is also increasingly used in the detection of MET gene abnormalities. At present, no single method can guarantee the comprehensive detection of all c-MET mutations. The combination of multiple methods is more conducive to comprehensive judgment and accurate screening of suitable patients.

"Chinese Expert Consensus on MET Clinical Testing in Non-small cell Lung Cancer" indicates that: The MET exon14 skipping is one of the driver gene mutations in advanced NSCLC, and is an important biomarker for screening people who can benefit from targeted therapy with MET inhibitors. MET gene amplification is the primary driver gene variation of NSCLC, and is also one of the important mechanisms of drug resistance of EGFR-TKI and ALK-TKI. It can be used as a potential molecular marker of combined targeted therapy after drug resistance in advanced patients. Clinical should paid attention to MET gene amplification detection. MET protein overexpression has potential guiding value in the clinical treatment of NSCLC MET inhibitors, and the benefit threshold of different patient populations needs further study.

NCCN guidelines recommend the detection of  MET exon14 skipping and MET amplification in patients with non-small cell lung cancer.

MEDx has conducted in-depth research on MET related biomarkers based on the integrated translational medicine technology platform, such as IHC, FISH, ARMS Q-PCR, NGS, and methods have been fully validated. Meanwhile, the MET Ex14Del PCR Kit of MEDx https://www.medxtmc.net/PCR_Based_Assays/MET_Ex14Del_PCR_Kit.shtml has obtained CE certification, which can meet the different needs of innovative pharmaceutical companies and clinical.

 

If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.


1. Customized or bulk orders of IVD/CDx products.

2. Get a quote for IVD/CDx products

3. Become our distributor

4. Get customized pharmaceutical service solutions

5.Learn more about our technology and R&D


Show of MEDx by CCTV